Nippon Shinyaku Co.,Ltd. Logo

Nippon Shinyaku Co.,Ltd.

Develops pharmaceuticals and functional foods to improve healthcare and wellbeing.

4516 | T

Overview

Corporate Details

ISIN(s):
JP3717600005
LEI:
Country:
Japan
Address:
京都市南区吉祥院西ノ庄門口町14番地
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Nippon Shinyaku Co., Ltd. is a research and development-oriented company engaged in the manufacturing and commercialization of pharmaceuticals and functional foods. The company's core business is its Pharmaceuticals division, which develops and sells a range of prescribed drugs, including specialty and generic medications, with a focus on therapeutic areas such as urinary, neurological, respiratory, and circulatory disorders. The Functional Foods division leverages the company's pharmaceutical expertise to produce and market high-quality health food products. Nippon Shinyaku is committed to supplying original, high-quality products to contribute to the healthcare sector and improve wellbeing.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-14 06:45
Registration Form
確認書
Japanese 8.7 KB
2025-11-14 06:43
Interim Report
半期報告書-第163期(2025/04/01-2026/03/31)
Japanese 233.6 KB
2025-07-04 06:16
Post-Annual General Meeting Information
臨時報告書
Japanese 27.7 KB
2025-06-24 06:23
Registration Form
確認書
Japanese 8.6 KB
2025-06-24 06:22
Governance Information
内部統制報告書-第162期(2024/04/01-2025/03/31)
Japanese 26.1 KB
2025-06-24 06:18
Annual Report
有価証券報告書-第162期(2024/04/01-2025/03/31)
Japanese 1.6 MB
2024-11-14 02:12
Report Publication Announcement
確認書
Japanese 8.6 KB
2024-11-14 02:11
Interim Report
半期報告書-第162期(2024/04/01-2025/03/31)
Japanese 233.5 KB
2024-07-01 04:04
Post-Annual General Meeting Information
臨時報告書
Japanese 29.3 KB
2024-06-28 04:07
Governance Information
内部統制報告書-第161期(2023/04/01-2024/03/31)
Japanese 23.3 KB
2024-06-28 04:01
Registration Form
確認書
Japanese 8.6 KB
2024-06-28 03:58
Annual Report
有価証券報告書-第161期(2023/04/01-2024/03/31)
Japanese 1.5 MB
2024-02-14 02:06
Report Publication Announcement
確認書
Japanese 8.6 KB
2024-02-14 02:05
Quarterly Report
四半期報告書-第161期第3四半期(2023/10/01-2023/12/31)
Japanese 244.8 KB
2023-11-14 01:59
Report Publication Announcement
確認書
Japanese 8.6 KB

Automate Your Workflow. Get a real-time feed of all Nippon Shinyaku Co.,Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Nippon Shinyaku Co.,Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Nippon Shinyaku Co.,Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

ArcticZymes Technologies Logo
Develops novel enzymes from Arctic organisms for diagnostics, therapeutics, and biopharma.
Norway
AZT
Arcturus Therapeutics Holdings Inc. Logo
Develops mRNA therapeutics and vaccines for rare respiratory, liver, and infectious diseases.
United States of America
ARCT
Arcus Biosciences, Inc. Logo
A clinical-stage biopharma developing small molecule and antibody combination therapies for cancer.
United States of America
RCUS
Arcutis Biotherapeutics, Inc. Logo
Develops and commercializes non-steroidal therapies for immune-mediated skin diseases.
United States of America
ARQT
ARDELYX, INC. Logo
Biopharma developing first-in-class drugs for cardiorenal and GI diseases like IBS-C and CKD.
United States of America
ARDX
ARECOR THERAPEUTICS PLC Logo
Biopharma firm enhancing drugs via reformulation for diabetes and pharmaceutical partners.
United Kingdom
AREC
argenx SE Logo
Develops first-in-class antibody therapies for severe autoimmune diseases.
Netherlands
1AE
Armata Pharmaceuticals, Inc. Logo
Developing bacteriophage therapeutics for antibiotic-resistant infections.
United States of America
ARMP
AroCell AB Logo
Develops and markets diagnostic tests for monitoring cancer and bacterial diseases.
Sweden
AROC
ArriVent BioPharma, Inc. Logo
A clinical-stage biopharma developing in-licensed oncology drugs for difficult-to-treat diseases.
United States of America
AVBP

Talk to a Data Expert

Have a question? We'll get back to you promptly.